Skip to main content
REGN logo

REGN · Regeneron Pharmaceuticals, Inc.

Track REGN — free
$955.47 +4.28 (+0.45%) At close · Nov 13
Market Cap
$98.84B
Shares
103.45M
Volume · Nov 13 1.17M Avg daily vol (3M) 792.82K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$955.47 Open$952.47 Day$942.00–961.94 52W close$600.66–973.36 Avg vol 30d890K Short int2.2M · 2.1% of shares · 2.7d Short vol42% Last earningsOct 30, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 30

Up next

Jan 29, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Oct 30
Earnings call
Revenue and EPS surge; semdiceran decision expected in November

Regeneron Pharmaceuticals reported third-quarter revenue of $5.1 billion, up 36%, and non-GAAP diluted EPS of $20.07, up 70%. It expects an FDA decision in November for semdiceran in generalized myosthenia gravis.

3 source passages
Total revenue grew 36%, and non-GAAP earnings per share grew 70% compared to the third quarter of 2025. Third quarter total revenue increased 36% from the prior year to $5.1 billion, driven primarily by higher Sanofi collaboration revenue, along with strong growth from both LibTayo and ILEA HD. Third quarter, diluted net income per share grew 70% to $20.07 on net income of $2.2 billion. In neuromuscular disease, we expect an FDA decision in November for semdiceran in generalized myosinia gravis. Open the document at this passage
Oct 30
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Regeneron Pharmaceuticals, Inc. expanded its Sanofi collaboration in October 2026 to include four additional antibodies, receiving a $1.0 billion up-front payment and up to $7.0 billion in milestones.

Revenue $5.12B ▲ 36.3% Net income $1.95B ▲ 33.5% Diluted EPS $18.45 ▲ 35.5%
Read from the MD&A section
Oct 30
Current report 8-K
Financial results

Regeneron Pharmaceuticals reported third-quarter 2026 revenues of $5.1 billion, up 36%, and non-GAAP EPS of $20.07, up 70%. Its expanded Sanofi alliance adds $1.0 billion upfront and up to $7.0 billion in future milestones.

Oct 6
Current report 8-K Events of Oct 1
Entered into a material agreement, Financial results, Other events

Regeneron and Sanofi agreed to co-develop four antibodies, with a $1.0 billion upfront payment and up to $7.0 billion in milestones. Regeneron expects an approximately $22 million pre-tax IPR&D charge and approximately $0.18 diluted-share impact in third quarter 2026.

Oct 1
Investor event
Regeneron & Sanofi Investor Event

Regeneron expanded its collaboration with Sanofi to add next-generation type 2 medicines. Regeneron will contribute four long-acting antibodies and receive $1 billion upfront plus up to $7 billion in milestones; the companies will split development costs and global profits 50-50.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$16.90B
Trailing 12 months
Net income (TTM)
$4.82B
Trailing 12 months
Revenue growth YoY
+36.3%
Year over year
Operating margin
28.8%
Trailing 12 months
P / E (TTM)
21.1
Trailing earnings · reciprocal yield 4.7%
FCF yield
3.9%
TTM · current market cap
Return on invested capital
15.3%
Trailing 12 months
Net cash
$6.59B
Latest balance sheet
Dividend yield
0.4%
Trailing 12 months
Shares change YoY
-1.5%
Year over year · fewer shares
Price change (1Y)
+37.5%
Trailing year
Short interest
2.1%
Latest settlement · 2.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026
Q2 FY26

TL;DR. Regeneron reported Q2 2026 revenue up 17% to $4.3 billion and non-GAAP EPS up 11% to $14.29, with Dupixent, EYLEA HD, and Libtayo setting all-time-high quarterly net sales. The company fully repaid the Sanofi Development Balance, which will step up collaboration profits starting in Q3, and raised its 2026 non-GAAP gross margin outlook.

Bullish
  • + Total revenue grew 17% to $4.3 billion and non-GAAP EPS grew 11% to $14.29, marking a second consecutive quarter of double-digit top- and bottom-line growth
  • + Dupixent global net sales reached an all-time high of $6.0 billion, up 38%, with U.S. sales up 42% to $4.6 billion
  • + EYLEA HD U.S. net sales rose 52% to an all-time high of $596 million and now represent ~60% of the U.S. retinal franchise
  • + Sanofi Development Balance fully repaid; collaboration profits step up beginning Q3 2026
  • + Raised 2026 non-GAAP gross margin on net product sales guidance to 84%-85% (from 83%-84%)
Bearish
  • − EYLEA U.S. net sales fell 45% to $412 million due to conversion to EYLEA HD, competition, and upcoming aflibercept biosimilars
  • − Fianlimab Phase 3 in first-line advanced melanoma did not meet statistical significance for the primary PFS endpoint
  • − GAAP net income declined 7% to $1,297 million and GAAP diluted EPS fell 5% to $12.23, weighed down by IPR&D charges and lower investment gains
  • − GAAP gross margin on net product sales fell to 78% from 83% due to unabsorbed manufacturing costs from the Limerick, Ireland facility interruption
  • − Q2 R&D expense rose 15% to $1,632 million and acquired IPR&D charges jumped to $127 million (vs. $10 million prior year), creating a $0.99 per-share non-GAAP drag

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +28%
above
Price vs 50-day avg +17%
above
RSI (14) 68
neutral
MACD trend Positive
52-week position 95%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +21%
trailing
6-month return +51%
trailing
YTD return +24%
this year
Relative strength +50%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $816 › 200d $747 — 50d above 200d
Institutional flow Distributing
1,281 of 1,354 funds reported for Sep 30 · net -439.6K sh shares · +157 new
Insider flow Distributing
Net -$43.3M over 90 days · 100% sells
Short interest Rising
2.14% of shares out · ▲ +3.8% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,354 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Excellent
Revenue growth +21%
Y/Y
EPS growth +8%
Y/Y
Valuation P/E 21.1
below peers
Buyback $2.2B
remaining
Balance sheet $412.2M
net cash
Quant / Vol
risk profile
Moderate
Volatility 34%
annualized · 1-yr
Max drawdown −26%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 30, 2026
GAAP R&D · full year 2026 Raised $6.6B – $6.74B
Jul 30, 2026 $6.5B – $6.64B changed to Oct 30, 2026 $6.6B – $6.74B
GAAP SG&A · full year 2026 Lowered $2.73B – $2.86B
Jul 30, 2026 $2.83B – $2.96B changed to Oct 30, 2026 $2.73B – $2.86B
Non-GAAP R&D(a) · full year 2026 $6.05B – $6.15B
GAAP gross margin on net product sales · full year 2026 Raised 80%
Jul 30, 2026 78% – 79% changed to Oct 30, 2026 80%
Non-GAAP SG&A(a) · full year 2026 $2.4B – $2.5B
Non-GAAP gross margin on net product sales(a) · full year 2026 86%
GAAP effective tax rate · full year 2026 Raised 14%
Jul 30, 2026 13% – 14% changed to Oct 30, 2026 14%
Non-GAAP COCM(a) · full year 2026 $970M – $1.02B
GAAP COCM · full year 2026 Maintained $985M – $1.04B
Jul 30, 2026 $985M – $1.04B changed to Oct 30, 2026 $985M – $1.04B
Non-GAAP effective tax rate(a) · full year 2026 15%
Previous outlook earlier release · from the 8-K filed Jul 30, 2026

Still-open targets the latest release did not restate under the same label.

Non-GAAP R&D · full year 2026 $5.95B – $6.05B
Non-GAAP SG&A · full year 2026 $2.5B – $2.6B
Non-GAAP gross margin on net product sales · full year 2026 84% – 85%
Non-GAAP COCM · full year 2026 $970M – $1.02B
Capital expenditures · full year 2026 $1.03B – $1.1B
Non-GAAP effective tax rate · full year 2026 14% – 15%
Prior guidance period ended · from the 8-K filed Oct 6, 2026
Acquired in-process research and development ("IPR&D") charge · third quarter 2026 $22M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+28% Bullish
Price vs 50-day avg
+17% Bullish
RSI (14)
68 Neutral
MACD trend
Positive Bullish
52-week position
95% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $816 › 200d $747 — 50d above 200d
Institutional flow Distributing
1,281 of 1,354 funds reported for Sep 30 · net -439.6K sh shares · +157 new
Insider flow Distributing
Net -$43.3M over 90 days · 100% sells
Short interest Rising
2.14% of shares out · ▲ +3.8% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,354 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $601 Now $955 · 95% Range high $973
vs 200-day avg +28% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
aggregate payments $150M first quarter of 2026 filing —
Capital expenditures -771M Nine Months Ended September 30, 2026 —
Company's share of profits from the commercialization of antibodies 2.58B Q3 2026 —
Customer A 48% the three months ended September 30, 2026 filing —
Customer B 30% the three months ended September 30, 2026 filing —
Evkeeza® - U.S. 55M Q3 2026 —
EYLEA HD U.S. net sales 699M Q3 2026 —
EYLEA U.S. net product sales declined 41% the three months ended September 30, 2026 filing —
EYLEA® - U.S. 400M Q3 2026 —
Free cash flow non-GAAP 2.9B Nine Months Ended September 30, 2026 —
Gross margin on net product sales 82% three months ended September 30, 2026 filing —
Libtayo - ROW 154M Q3 2026 —
Libtayo - U.S. 396M Q3 2026 —
Other products(e) 91.3M Three Months Ended September 30, 2026 filing —
Praluent(d) 260.9M Three Months Ended September 30, 2026 filing —
Praluent® - U.S. 81M Q3 2026 —
product candidates in clinical development 50 Q3 2026 —
reduced liver fat 70% 12 weeks —
Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 38% three months ended September 30, 2026 filing —
Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside t 33% three months ended September 30, 2026 filing —
Total EYLEA HD and EYLEA 1.74B Three Months Ended September 30, 2026 filing —
Total EYLEA HD and EYLEA - U.S. 1.1B Q3 2026 —
up-front payment 1B October 2026 —
Net product sales of Praluent (Total) $265.6M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
REGN
Regeneron Pharmaceuticals, Inc.
this stock
$98.84B +23.8% +20.8% 21.1 2.1%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
MRNA
Moderna, Inc.
$90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%
ARGX
Argenx SE
$60.37B +14.2% — — 2.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,454
% held
87.9%
Reported
1,281 of 1,354
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,105
View
Short & Settlement
Short Interest Rising
Shares short
2.2M
Days to cover
2.7d
Change
+82.2K sh
View
Short Volume
Short vol %
42%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
8
Value
$6.2K
As of
Sep 17, 2026
View
Off-Exchange
Off-exchange %
44.2%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$43.3M
Buyers / Sellers
0 / 5
Buyers Sellers
View
Congressional Trades Sell
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
May 15, 2026
View
Financials
Financials
Revenue (FY)
$14.3B
Net income (FY)
$4.5B
EPS diluted
$41.48
View
Buybacks
Authorized
$3.0B
Remaining
$2.2B
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 30, 2026
This year
23

Regeneron Pharmaceuticals, Inc. expanded its Sanofi collaboration in October 2026 to include four additional antibodies, receiving a $1.0 billion up-front payment and up to $7.0 billion in milestones.

View
Proposed Sales
Value
$3.8M
Shares
3.9K
Filed
Nov 4, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 17, 2026
Last webcast
Oct 30, 2026
View
Investor Relations
Latest news
Regeneron Announces Investor Conf…
Published
Nov 2, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
REGN +5.7% +20.8% +50.6% +3.0% +23.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +3.1% +22.0% +50.1% +3.2% +13.2%

Capital returns

Latest dividend
$0.94 / share · ex Aug 18, 2026
Declared · upcoming
$0.94 / share · ex Nov 20, 2026
Raised 6.8%
Paid (TTM)
$3.70 / share · 4 payouts
Dividend yield (TTM, derived)
0.39%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$3.00B
Spent (derived)
$843.00M
Remaining
$2.16B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 872589 CUSIP 75886F107 13F (30d) 1105 filings 1038 filers Visit website Investor relations